{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=23", "query": { "condition": "Endometrium Cancer", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 791, "total_pages": 80, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrium+Cancer&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T02:47:18.362Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "HR+ Breast Cancer", "CCNE1 Amplification", "HER2-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Gastric Cancer", "Esophageal Adenocarcinoma", "Carcinosarcoma" ], "interventions": [ { "name": "BLU-222", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-04-07", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252416" }, { "nct_id": "NCT07444814", "title": "Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Ovarian Cancer Metastatic", "Ovarian Cancer Metastatic Recurrent", "Non-squamous EGFR Wt NSCLC", "Platinum Resistant Ovarian Cancer", "PROC" ], "interventions": [ { "name": "HWK-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Whitehawk Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2025-12-19", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444814" }, { "nct_id": "NCT07107334", "title": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrioid Endometrial Adenocarcinoma" ], "interventions": [ { "name": "Glucagon-like peptide 1 receptor agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2026-04-07", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107334" }, { "nct_id": "NCT00788671", "title": "Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Endometrial Hyperplasia", "Stage I Uterine Corpus Cancer AJCC v7", "Stage IA Uterine Corpus Cancer AJCC v7", "Stage IB Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Levonorgestrel-Releasing Intrauterine System", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 69, "start_date": "2008-11-03", "completion_date": "2027-11-30", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 7, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788671" }, { "nct_id": "NCT00523432", "title": "A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Genital Neoplasms, Female" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "CCI-779 (temsirolimus)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2007-08", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00523432" }, { "nct_id": "NCT07737795", "title": "Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "OK-1 & Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 66, "start_date": "2026-08", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07737795" }, { "nct_id": "NCT03899441", "title": "Multimedia Aid Gynecologic Counseling and Consent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrium Cancer", "Sentinel Lymph Node", "Perioperative/Postoperative Complications" ], "interventions": [ { "name": "Video", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2018-10-01", "completion_date": "2020-04-01", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899441" }, { "nct_id": "NCT00001837", "title": "Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Breast Neoplasm" ], "interventions": [], "intervention_types": [], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "1998-11", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001837" }, { "nct_id": "NCT00899496", "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 54, "start_date": "2005-09", "completion_date": "2009-10-23", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899496" }, { "nct_id": "NCT03018249", "title": "Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma", "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma", "FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Hysterectomy", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Medroxyprogesterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2017-10-11", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-10-25T02:47:18.362Z", "location_count": 234, "location_summary": "Hot Springs, Arkansas • Concord, California • Walnut Creek, California + 158 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03018249" } ] }